Seer, Inc. (SEER)
Nasdaq · Healthcare · Biotechnology
$2.33+3.56%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $129M
- 52-week range
- $1.55 – $2.41
- 52-week change
- −0.44%
- EPS (trailing)
- −$1.22
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $16.6M (+16.99%)
- Net income
- −$73.6M
- Operating margin
- −470.5%
- Free cash flow
- −$46.2M
From the company’s annual report on SEC EDGAR.
About Seer, Inc.
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes.
Headquarters: Redwood City, United States · 124 employees · seer.bio